Home / News / International / Cadila Healthcare’s arm gets one observation for Ahmedabad plant from USFDA

Cadila Healthcare’s arm gets one observation for Ahmedabad plant from USFDA

The US Food and Drug Administration (USFDA) has conducted a Pre-Approval Inspection (PAI) for Doxorubicin Liposomal, a complex oncological injectable at Alidac Pharmaceuticals, the injectable onco manufacturing facility, located at Pharmez, Ahmedabad from March 18 to 26, 2019. The inspection concluded with one observation.

Alidac Pharmaceuticals is a 100% subsidiary of Cadila Healthcare. The company is addressing these observations and is confident of getting the product approval at the earliest.

Cadila Healthcare is an India-based pharmaceutical company. The company’s subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

x

Check Also

Gold Gains As US Recession Fears Boost Safe-Haven Assets

Gold Gains As US Recession Fears Boost Safe-Haven Assets

Gold rose on Monday as investors’ appetite for riskier assets faded on ...

IOC surges on acquiring Abu Dhabi Onshore Block 1

IOC surges on acquiring Abu Dhabi Onshore Block 1

Mumbai : Indian Oil Corporation (IOC) is currently trading at Rs. 158.70, ...